Why some diabetes drugs protect the heart
Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Lowering LDL cholesterol had no significant association with reduced heart events.
For 40+ years, medicine has told us 'lower LDL = lower heart risk.' This study says: not when you’re on GLP-1 drugs. The effect vanished despite LDL dropping.
Practical Takeaways
If you're on a GLP-1 drug like Ozempic or Wegovy, focus on maximizing weight loss and HbA1c reduction—not just chasing cholesterol or BP numbers.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Lowering LDL cholesterol had no significant association with reduced heart events.
For 40+ years, medicine has told us 'lower LDL = lower heart risk.' This study says: not when you’re on GLP-1 drugs. The effect vanished despite LDL dropping.
Practical Takeaways
If you're on a GLP-1 drug like Ozempic or Wegovy, focus on maximizing weight loss and HbA1c reduction—not just chasing cholesterol or BP numbers.
Publication
Journal
Cardiovascular Drugs and Therapy
Year
2024
Authors
D. Gomes, J. Presume, P. de Araújo Gonçalves, Manuel S. Almeida, Miguel Mendes, Jorge Ferreira
Related Content
Claims (6)
GLP-1 diabetes drugs help prevent heart attacks and strokes mainly by lowering blood sugar and helping people lose weight—not by lowering blood pressure or bad cholesterol.
For people with type 2 diabetes, lowering their blood sugar by 1% using certain diabetes medications is linked to a 25% lower chance of having a heart attack, stroke, or dying from heart disease.
Losing just 1 kilogram (about 2.2 pounds) of body weight while taking GLP-1 diabetes drugs is linked to a 7% lower chance of having a heart attack, stroke, or dying from heart disease.
GLP-1 diabetes drugs that lower blood sugar and weight the most tend to offer the biggest protection against heart attacks and strokes in people with type 2 diabetes.
GLP-1 receptor agonists reduce cardiovascular event rates independently of LDL cholesterol modulation, primarily through weight loss and improved metabolic health.